Screener
LB Pharmaceuticals Inc LBRX Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by LB Pharmaceuticals Inc in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The source filing: LB Pharmaceuticals Inc’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-219607
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Depreciation | 82 | 79 |
| Noncash lease expense | 50 | 133 |
| Realized gain on sale of marketable securities, net | — | (119) |
| Amortization (accretion) of premium (discounts) on investments, net | 17 | (12) |
| Gain on change in fair value of derivative instruments | (200) | (768) |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (10,219) | 83 |
| Operating lease liabilities | (99) | 2 |
Item 1. Financial Statements
FAQ
- What is LB Pharmaceuticals Inc's accretion (amortization) of discounts and premiums, investments?
- LB Pharmaceuticals Inc (LBRX) reported accretion (amortization) of discounts and premiums, investments of -$17K in Q1 2026.
- What does accretion (amortization) of discounts and premiums, investments mean?
- Measures the non-cash adjustments to the carrying value of investment securities resulting from the amortization of premiums or the accretion of discounts over the life of the instrument. This reflects the effective interest income earned on the company's investment portfolio beyond the stated coupon payments.
Ask your AI about LB Pharmaceuticals Inc's accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude